p.69 抽出テキスト

CLINICAL STATEMENTS AND GUIDELINES

Circulation. 2025;151:e771–e862. DOI: 10.1161/CIR.0000000000001309 April 1, 2025 e839

7.	 Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018;391:1693–1705. 8.	 Yu Y, Wang J, Wang Q, et al. Admission oxygen saturation and all-cause in-hospital mortality in acute myocardial infarction patients: data from the MIMIC-III database. Ann Transl Med. 2020;8:1371. 9.	 Hofmann R, Witt N, Lagerqvist B, et al. Oxygen therapy in ST-elevation myocardial infarction. Eur Heart J. 2018;39:2730–2739. 10.	 James SK, Erlinge D, Herlitz J, et al. Effect of oxygen therapy on cardiovas-

cular outcomes in relation to baseline oxygen saturation. J Am Coll Cardiol Intv. 2020;13:502–513. 4.2. Analgesics 1.	 GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet. 1994;343:1115–1122. 2.	 ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669–685. 3.	 Shotan A, Brill Z, Matetzky S, et al. Pain scoring-a method for assessing acute antianginal therapy comparison of the response to acute sublingual administration of an isosorbide dinitrate tablet, isosorbide dinitrate spray and nitroglycerin spray in unstable angina. Cardiology. 1998;89:163–169. 4.	 Bosson N, Isakson B, Morgan JA, et al. Safety and effectiveness of field nitroglycerin in patients with suspected ST elevation myocardial infarction. Prehosp Emerg Care. 2019;23:603–611. 5.	 Parodi G. Chest pain relief in patients with acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2016;5:277–281. 6.	 Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149:1043–1049. 7.	 Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37:245–252. 8.	 Ibrahim K, Shah R, Goli RR, et al. Fentanyl delays the platelet inhibition effects of oral ticagrelor: full report of the PACIFY randomized clinical trial. Thromb Haemost. 2018;118:1409–1418. 9.	 Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63:630–635. 10.	 Thomas MR, Morton AC, Hossain R, et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost. 2016;116:96–102. 11.	 Lapostolle F, van’t Hof AW, Hamm CW, et al. Morphine and ticagrelor interaction in primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: ATLANTIC-Morphine. Am J Cardiovasc Drugs. 2019;19:173–183. 12.	 Furtado RHM, Nicolau JC, Guo J, et al. Morphine and cardiovascular outcomes among patients with non-ST-segment elevation acute coronary syndromes undergoing coronary angiography. J Am Coll Cardiol. 2020;75:289– 300. 13.	 Batchelor R, Liu DH, Bloom J, et al. Association of periprocedural intravenous morphine use on clinical outcomes in ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention: systematic review and meta-analysis. Catheter Cardiovasc Interv. 2020;96:76–88. 14.	 Lee SW, Kuo N, Hou SK, et al. Effects of morphine and P2Y inhibitor amongst patients with acute coronary syndrome: a meta-analysis of comparative studies. Am J Emerg Med. 2023;70:119–126. 15.	 Schmidt M, Lamberts M, Olsen AM, et al. Cardiovascular safety of nonaspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016;37:1015–1023. 16.	 Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123:2226–2235. 17.	 Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarc-

tion associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906–2913. 18 Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients

taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ. 2005;330:1366. 19.	 Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634–1642. 20.	 Doucet S, Malekianpour M, Theroux P, et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation. 2000;101:955–961. 21.	 Karlberg KE, Saldeen T, Wallin R, et al. Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: a double-blind placebo-controlled study. J Intern Med. 1998;243:25–31. 22.	 Perez MI, Musini VM, Wright JM. Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event. Cochrane Database Syst Rev. 2009;CD006743. 23.	 Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42:1855–1860. 24.	 Parker JD, Bart BA, Webb DJ, et al. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med. 2007;35:1863–1868. 25.	 Swearingen D, Nehra A, Morelos S, et al. Hemodynamic effect of avanafil

and glyceryl trinitrate coadministration. Drugs Context. 2013;2013:212248.

4.3.1 Aspirin 1.	 Antithrombotic Trialists Collaboration. Collaborative meta-analysis of ran-

domised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86. 2.	 Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860. 3.	 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–360. 4.	 Mehta SR, Bassand JP, Chrolavicius S, et al. Current Oasis Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930–942. 5.	 Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;384:1981–1990. 6.	 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106. 7.	 Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA. 2004;292:3017– 3023. 8.	 Cortellini G, Raiteri A, Galli M, et al. Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease. J Thromb Thrombolysis. 2023;55:762–769. 9.	 Chopra AM, Diez-Villanueva P, Cordoba-Soriano JG, et al. Meta-analysis of acetylsalicylic acid desensitization in patients with acute coronary syndrome. Am J Cardiol. 2019;124:14–19. 10.	 Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383. 11.	 Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopi-

dogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544–554. 4.3.2. Oral P2Y12 Inhibitors During Hospitalization 1.	 Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502. 2.	 Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–1189. 3.	 Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–1621. 4.	 Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in

patients with acute coronary syndromes. N Engl J Med. 2007;357:2001– 2015.

Downloaded from http://ahajournals.org by on October 7, 2026